Bristol-Myers Squibb Company (BMY) : Bristol-Myers Squibb Company (BMY) had a healthy money flow of $1.3 million into the stock during the Mondays trading session. The value of bullish trades on upticks was $87.65 million, whereas, investors only sold shares worth $86.34 million on downticks. The stock closed the day with an up-down ratio of 1.02.The money flow in the block trades to the tune of $2.81 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $9.91 million worth of transactions were on upticks. A paltry $7.1 million worth of block trade transactions on downticks shows that the investors are reluctant to sell the stock down. The total up-down ratio of the upticks vs the downticks in block trades was 1.4. Bristol-Myers Squibb Company (BMY) stock slid $0.07 intraday and traded at 60.56, a change of -0.12% over previous days close. However, for the week, the company shares are -4.3% compared to previous weeks close.
Bristol-Myers Squibb Company has lost 0.45% in the last five trading days and dropped 21.01% in the last 4 weeks. Bristol-Myers Squibb Company has dropped 17.14% during the last 3-month period . Year-to-Date the stock performance stands at -11.75%.
Bristol-Myers Squibb Company (NYSE:BMY): The stock opened at $60.74 on Monday but the bulls could not build on the opening and the stock topped out at $60.86 for the day. The stock traded down to $60.01 during the day, due to lack of any buying support eventually closed down at $60.03 with a loss of -0.99% for the day. The stock had closed at $60.63 on the previous day. The total traded volume was 12,142,914 shares.
In a related news,The director of Bristol Myers Squibb Co, Andreotti Lamberto sold 23,200 shares at $74.65 on July 7, 2016. The Insider selling transaction had a total value worth of $1,731,880. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
Bristol-Myers Squibb Company (BMS) is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products across the world. The Companys products are sold to wholesalers, retail pharmacies, hospitals, government entities and the medical profession. The Company manufactures its products in the United States, Puerto Rico and in six foreign countries. The Company promotes the use of its products directly to healthcare professionals and providers, such as doctors, nurse practitioners, physician assistants, pharmacists, technologists, hospitals, Pharmacy Benefit Managers (PBMs) and Managed Care Organizations (MCOs). It also provides information about the use of its products to consumers in the United States through direct-to-consumer print, radio, television, and digital advertising and promotion. In addition, the Company holds rights to F001287, which is a preclinical, small-molecule IDO1-inhibitor.